Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Norbert Gattermann

Showing results (71-80 of 158) with videos related to

Pageof 16
Sort By:
Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis|December 28, 2007
Fatal bleeding due to a heparin-like anticoagulant in a 37-year-old woman suffering from systemic mastocytosisChristoph Sucker, Georg Mansmann, Stefan Steiner, et al.
Experimental Hematology|April 29, 2008
Analysis of mitochondrial DNA in 104 patients with myelodysplastic syndromesMichael Wulfert, Anna C Küpper, Christoph Tapprich, et al.
Expert Review of Anticancer Therapy|July 24, 2020
Improving the accuracy of prognostication in chronic myelomonocytic leukemiaJennifer Kaivers, Esther Schuler, Barbara Hildebrandt, et al.
Annals of Hematology|November 5, 2005
Results of a phase 2 study of valproic acid alone or in combination with all-trans retinoic acid in 75 patients with myelodysplastic syndrome and relapsed or refractory acute myeloid leukemiaAndrea Kuendgen, Sabine Knipp, Frank Fox, et al.
Annals of Hematology|June 10, 2026
Prognostic impact of bone marrow iron and serum ferritin in patients with myelodysplastic syndromesAnnika Kasprzak, Felicitas Schulz, Kathrin Nachtkamp, et al.
Leukemia Research|March 22, 2017
New proposals of the WHO working group (2016) for the diagnosis of myelodysplastic syndromes (MDS): Characteristics of refined MDS typesCorinna Strupp, Kathrin Nachtkamp, Barbara Hildebrandt, et al.
Annals of Hematology|May 6, 2017
A retrospective study evaluating the impact of infectious complications during azacitidine treatmentAnna Schuck, Marie-Christine Goette, Judith Neukirchen, et al.
Cancer|July 27, 2017
Cytogenetic clonal evolution in myelodysplastic syndromes is associated with inferior prognosisJudith Neukirchen, Michael Lauseker, Barbara Hildebrandt, et al.
Clinical Lymphoma, Myeloma & Leukemia|February 17, 2019
Clinical Benefit-Risk Profile of Lenalidomide in Patients With Lower-risk Myelodysplastic Syndromes Without del(5q): Results of a Phase III TrialGuillermo Garcia-Manero, Antonio Almeida, Pierre Fenaux, et al.
Haematologica|January 28, 2014
The myelodysplastic syndrome-comorbidity index provides additional prognostic information on patients stratified according to the revised international prognostic scoring systemEsther Zipperer, Nina Tanha, Corinna Strupp, et al.
Pageof 16

Showing results (71-80 of 158) with videos related to

Sort By:
Pageof 16
Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis|December 28, 2007
Fatal bleeding due to a heparin-like anticoagulant in a 37-year-old woman suffering from systemic mastocytosisChristoph Sucker, Georg Mansmann, Stefan Steiner, et al.
Experimental Hematology|April 29, 2008
Analysis of mitochondrial DNA in 104 patients with myelodysplastic syndromesMichael Wulfert, Anna C Küpper, Christoph Tapprich, et al.
Expert Review of Anticancer Therapy|July 24, 2020
Improving the accuracy of prognostication in chronic myelomonocytic leukemiaJennifer Kaivers, Esther Schuler, Barbara Hildebrandt, et al.
Annals of Hematology|November 5, 2005
Results of a phase 2 study of valproic acid alone or in combination with all-trans retinoic acid in 75 patients with myelodysplastic syndrome and relapsed or refractory acute myeloid leukemiaAndrea Kuendgen, Sabine Knipp, Frank Fox, et al.
Annals of Hematology|June 10, 2026
Prognostic impact of bone marrow iron and serum ferritin in patients with myelodysplastic syndromesAnnika Kasprzak, Felicitas Schulz, Kathrin Nachtkamp, et al.
Leukemia Research|March 22, 2017
New proposals of the WHO working group (2016) for the diagnosis of myelodysplastic syndromes (MDS): Characteristics of refined MDS typesCorinna Strupp, Kathrin Nachtkamp, Barbara Hildebrandt, et al.
Annals of Hematology|May 6, 2017
A retrospective study evaluating the impact of infectious complications during azacitidine treatmentAnna Schuck, Marie-Christine Goette, Judith Neukirchen, et al.
Cancer|July 27, 2017
Cytogenetic clonal evolution in myelodysplastic syndromes is associated with inferior prognosisJudith Neukirchen, Michael Lauseker, Barbara Hildebrandt, et al.
Clinical Lymphoma, Myeloma & Leukemia|February 17, 2019
Clinical Benefit-Risk Profile of Lenalidomide in Patients With Lower-risk Myelodysplastic Syndromes Without del(5q): Results of a Phase III TrialGuillermo Garcia-Manero, Antonio Almeida, Pierre Fenaux, et al.
Haematologica|January 28, 2014
The myelodysplastic syndrome-comorbidity index provides additional prognostic information on patients stratified according to the revised international prognostic scoring systemEsther Zipperer, Nina Tanha, Corinna Strupp, et al.
Pageof 16